Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Mantle-Cell 12Lymphoma, Non-Hodgkin 10Recurrence 9Lymphoma, B-Cell 9Lymphoma 8Dendritic Cell Sarcoma, Interdigitating 3Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Cytokine Release Syndrome 1Ann Arbor Stage II Mantle Cell Lymphoma 1Aggression 1

Interventions

Cyclophosphamide 37fludarabine phosphate 27Peripheral Blood Stem Cell Transplantation 24Whole-Body Irradiation 18Etoposide 18Doxorubicin 17Vincristine 16Mycophenolic Acid 16Cyclosporine 16Prednisone 15Tacrolimus 12Busulfan 12Bortezomib 12Methotrexate 11Antilymphocyte Serum 11Rituximab 10Melphalan 10Gemcitabine 9Carboplatin 9Lenalidomide 8Filgrastim 8Vorinostat 7Radiotherapy 7Everolimus 7Alemtuzumab 6romidepsin 5Methylprednisolone 5Ifosfamide 5Flow Cytometry 5Cytarabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Immunoblastic Lymphadenopathy × glofitamab × Clear all
NCT06393738 2026-02-10

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Arvinas Inc.

Phase 1 Recruiting
255 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡